Equitable Access to Molecular Testing and Treatment Prioritization

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.